Zobrazit v EDS

Patient-Reported Outcomes After Switching to a 2-Drug Regimen of Fixed-Dose Combination Dolutegravir/Lamivudine: 48-Week Results from the SALSA Study

Uloženo v:
Podrobná bibliografie
Název: Patient-Reported Outcomes After Switching to a 2-Drug Regimen of Fixed-Dose Combination Dolutegravir/Lamivudine: 48-Week Results from the SALSA Study
Autoři: Princy Kumar, Amanda E. Clarke, Celia Jonsson-Oldenbüttel, Miguel García Deltoro, Simona Di Giambenedetto, Carlos Brites, Laurent Hocqueloux, Po-Liang Lu, James Oyee, Alan Oglesby, Brian Wynne, Bryn Jones, Lee A. Evitt, Dainielle Fox, Michelle Kisare, Julie Priest
Zdroj: AIDS Behav
AIDS AND BEHAVIOR
r-FIHGUV. Repositorio Institucional de Producción Científica de la Fundación de Investigación del Hospital General de Valencia
Fundación de Investigación del Hospital General de Valencia (FIHGUV)
Informace o vydavateli: Springer Science and Business Media LLC, 2024.
Rok vydání: 2024
Témata: Male, Adult, Original Paper, Pyridones, Anti-HIV Agents, Lamivudine, Surveys and Questionnaires [MeSH], HIV Treatment Satisfaction Questionnaire, Drug Combinations [MeSH], HIV-1 [MeSH], Patient Satisfaction/statistics, Anti-HIV Agents/therapeutic use [MeSH], Piperazines [MeSH], Dolutegravir, Male [MeSH], Treatment experienced, Anti-HIV Agents/administration, Female [MeSH], HIV Infections/psychology [MeSH], Health-related quality of life, Adult [MeSH], HIV Symptom Distress Module, Humans [MeSH], Treatment Outcome [MeSH], HIV Integrase Inhibitors/therapeutic use [MeSH], Oxazines [MeSH], Lamivudine/administration, Middle Aged [MeSH], Viral Load [MeSH], Patient Reported Outcome Measures [MeSH], Heterocyclic Compounds, 3-Ring/therapeutic use [MeSH], Heterocyclic Compounds, 3-Ring/administration, HIV Integrase Inhibitors/administration, HIV Infections/drug therapy [MeSH], Lamivudine/therapeutic use [MeSH], Pyridones [MeSH], HIV Infections, Middle Aged, Viral Load, Piperazines, Drug Combinations, Treatment Outcome, Patient Satisfaction, Surveys and Questionnaires, Oxazines, HIV-1, Humans, Female, Patient Reported Outcome Measures, HIV Integrase Inhibitors, Heterocyclic Compounds, 3-Ring
Popis: Patient-reported outcomes (PROs) facilitate communication between patients and providers, enhancing patient-centered care. We report PROs for virologically suppressed people living with HIV-1 who switched to dolutegravir/lamivudine (DTG/3TC) or continued their 3- or 4-drug current antiretroviral regimen (CAR) in the phase 3 SALSA study. Secondary endpoints included change from baseline in HIV Treatment Satisfaction Questionnaire (status version; HIVTSQs) and HIV Symptom Distress Module (HIV-SDM) at Weeks 4, 24, and 48. A post hoc analysis assessed change in HIVTSQs and HIV-SDM by age (≥ 50 and
Druh dokumentu: Article
Other literature type
Jazyk: English
ISSN: 1573-3254
1090-7165
DOI: 10.1007/s10461-024-04479-9
Přístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/39225890
https://fihguv.fundanetsuite.com/publicaciones/ProdCientif/PublicacionFrw.aspx?id=2520
https://repository.publisso.de/resource/frl:6494294
Rights: CC BY NC ND
Přístupové číslo: edsair.doi.dedup.....73e1aebb889864c4021dfd14dcbe8f5e
Databáze: OpenAIRE
Popis
Abstrakt:Patient-reported outcomes (PROs) facilitate communication between patients and providers, enhancing patient-centered care. We report PROs for virologically suppressed people living with HIV-1 who switched to dolutegravir/lamivudine (DTG/3TC) or continued their 3- or 4-drug current antiretroviral regimen (CAR) in the phase 3 SALSA study. Secondary endpoints included change from baseline in HIV Treatment Satisfaction Questionnaire (status version; HIVTSQs) and HIV Symptom Distress Module (HIV-SDM) at Weeks 4, 24, and 48. A post hoc analysis assessed change in HIVTSQs and HIV-SDM by age (≥ 50 and
ISSN:15733254
10907165
DOI:10.1007/s10461-024-04479-9